These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

284 related items for PubMed ID: 19299495

  • 1. Costs and cost-effectiveness of four treatment regimens for latent tuberculosis infection.
    Holland DP, Sanders GD, Hamilton CD, Stout JE.
    Am J Respir Crit Care Med; 2009 Jun 01; 179(11):1055-60. PubMed ID: 19299495
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of 3 months of weekly rifapentine and isoniazid compared with other standard treatment regimens for latent tuberculosis infection: a decision analysis study.
    Doan TN, Fox GJ, Meehan MT, Scott N, Ragonnet R, Viney K, Trauer JM, McBryde ES.
    J Antimicrob Chemother; 2019 Jan 01; 74(1):218-227. PubMed ID: 30295760
    [Abstract] [Full Text] [Related]

  • 3. Potential economic viability of two proposed rifapentine-based regimens for treatment of latent tuberculosis infection.
    Holland DP, Sanders GD, Hamilton CD, Stout JE.
    PLoS One; 2011 Jan 01; 6(7):e22276. PubMed ID: 21789248
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. SIRCLE: a randomised controlled cost comparison of self-administered short-course isoniazid and rifapentine for cost-effective latent tuberculosis eradication.
    Denholm JT, McBryde ES, Eisen D, Street A, Matchett E, Chen C, Shultz TR, Biggs B, Leder K.
    Intern Med J; 2017 Dec 01; 47(12):1433-1436. PubMed ID: 29224209
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of latent tuberculosis infection testing and treatment with 6-week regimen among key population in rural communities in China: a decision analysis study.
    Cao X, Guo T, Xin H, Du J, Yang C, Feng B, He Y, Shen L, Di Y, Li Z, Chen Y, Liang J, Jin Q, Wang L, Gao L.
    Eur J Clin Microbiol Infect Dis; 2024 May 01; 43(5):809-820. PubMed ID: 38383889
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM, Christenson JC, Downs SM.
    Pediatrics; 2009 Mar 01; 123(3):816-22. PubMed ID: 19255008
    [Abstract] [Full Text] [Related]

  • 11. Potential cost-effectiveness of rifampin vs. isoniazid for latent tuberculosis: implications for future clinical trials.
    Esfahani K, Aspler A, Menzies D, Schwartzman K.
    Int J Tuberc Lung Dis; 2011 Oct 01; 15(10):1340-6. PubMed ID: 22283892
    [Abstract] [Full Text] [Related]

  • 12. Twelve months of isoniazid compared with four months of isoniazid and rifampin for persons with radiographic evidence of previous tuberculosis: an outcome and cost-effectiveness analysis.
    Jasmer RM, Snyder DC, Chin DP, Hopewell PC, Cuthbert SS, Antonio Paz E, Daley CL.
    Am J Respir Crit Care Med; 2000 Nov 01; 162(5):1648-52. PubMed ID: 11069790
    [Abstract] [Full Text] [Related]

  • 13. Potent twice-weekly rifapentine-containing regimens in murine tuberculosis.
    Rosenthal IM, Williams K, Tyagi S, Peloquin CA, Vernon AA, Bishai WR, Grosset JH, Nuermberger EL.
    Am J Respir Crit Care Med; 2006 Jul 01; 174(1):94-101. PubMed ID: 16574936
    [Abstract] [Full Text] [Related]

  • 14. An open label, randomised controlled trial of rifapentine versus rifampicin based short course regimens for the treatment of latent tuberculosis in England: the HALT LTBI pilot study.
    Surey J, Stagg HR, Yates TA, Lipman M, White PJ, Charlett A, Muñoz L, Gosce L, Rangaka MX, Francis M, Hack V, Kunst H, Abubakar I.
    BMC Infect Dis; 2021 Jan 21; 21(1):90. PubMed ID: 33478428
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Short-course prophylaxis against tuberculosis in HIV-infected persons. A decision and cost-effectiveness analysis.
    Rose DN.
    Ann Intern Med; 1998 Nov 15; 129(10):779-86. PubMed ID: 9841583
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis?
    Rosenthal IM, Zhang M, Almeida D, Grosset JH, Nuermberger EL.
    Am J Respir Crit Care Med; 2008 Nov 01; 178(9):989-93. PubMed ID: 18723432
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of rifampin for 4 months and isoniazid for 6 months in the treatment of tuberculosis infection.
    Pina JM, Clotet L, Ferrer A, Sala MR, Garrido P, Salleras L, Domínguez A.
    Respir Med; 2013 May 01; 107(5):768-77. PubMed ID: 23490222
    [Abstract] [Full Text] [Related]

  • 20. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM, Snyder DC, Saukkonen JJ, Hopewell PC, Bernardo J, King MD, Kawamura LM, Daley CL, Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection Study Investigators.
    Clin Infect Dis; 2004 Feb 01; 38(3):363-9. PubMed ID: 14727206
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.